

1
2
3
4
5
6 BIOTECHNOLOGY VALUE FUND, L.P.,
7 BIOTECHNOLOGY VALUE FUND II,
8 L.P., INVESTMENT 10, L.L.C., BVF
9 INVESTMENTS, L.L.C.; BVF INC., and
10 BVF X, LLC,

11 No. C 13-03248 WHA

12 Plaintiffs,

13 v.

14 CELERA CORPORATION, CREDIT
15 Suisse Securities (USA) LLC,
16 Kathy Ordoñez, Richard H.
17 Ayers, William G. Green, Peter
18 Barton Hutt, Gail M. Naughton,
Wayne I. Roe, and Bennett M.
Shapiro,

19 Defendants.

20 _____/

21 **ORDER SETTING
BRIEFING SCHEDULE AND
HEARING ON NON-PARTY
PHARMACYCLICS INC.'S
MOTION TO QUASH**

22 Pursuant to the order dated September 11, 2014, non-party Pharmacyclics Inc. has filed a
23 motion to quash plaintiffs' subpoena for certain drug valuation documents. However, given that
24 the discovery cut-off is October 21, 2014, this order hereby schedules the following briefing
deadlines and hearing date:

- 25 • If plaintiff wishes to respond to Pharmacyclics' motion to
26 quash, please do so by **4 PM ON SEPTEMBER 19, 2014**.
27 Please limit the response to no more than **TEN PAGES**.
28 • Any reply thereto is due by **4 PM ON SEPTEMBER 22, 2014**. Please limit any reply to **FIVE PAGES**.

- Hearing on the motion to quash is set for **8 AM ON SEPTEMBER 24, 2014.**

IT IS SO ORDERED.

Dated: September 16, 2014.

Wm. Alsup
WILLIAM ALSUP
UNITED STATES DISTRICT JUDGE